The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes

European Neuropsychopharmacology

Volumn 8, Issue 2, 1998, Pages 141-152

  Heresco Levy, Uriel ^a   Javitt, Daniel C ^b  

^a HERZOG HOSPITAL   (Israel)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Alcoholism; Depression; NMDA receptors; PTSD; Schizophrenia

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; CYCLOSERINE; DOPAMINE; EXCITATORY AMINO ACID; EXCITATORY AMINO ACID RECEPTOR; GLUTAMIC ACID; GLYCINE; MILACEMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

ALCOHOLISM; ARTICLE; CLINICAL TRIAL; DEPRESSION; HUMAN; LEARNING; MEMORY; MENTAL DISEASE; NEUROTRANSMISSION; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SCHIZOPHRENIA; SYNAPTOGENESIS;

ALCOHOLISM; DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; STRESS DISORDERS, POST-TRAUMATIC; SYNAPTIC TRANSMISSION;

EID: 0031897446     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00050-3     Document Type: Article

References (130)

1. Archibald H.C., Tuddenham R.D. Persistent stress reaction after combat. Arch. Gen. Psychiatry. 12:1965;475-481.
2. Artola A., Singer W. Long-term potentiation and NMDA receptors in rat visual cortex. Nature. 330:1987;649-652.
3. Benigno P., Monaco P. Analisi dell'effeto sedativo esercitato dal 1-4-amino-3-isossazolidone. Arch. Internat. Pharmacodyn. 124:1960;191-200.
4. Blier P., De Montigny C., Chaput Y. Modification of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 6(suppl):1987;24S-35S.
5. Bremner J.D., Steinberg M., Southwick S.M., Johnson D.R., Charney D.S. Use of the Structured Clinical Interview for DSM-IV Dissociative Disorders for systematic assessment of dissociative symptoms in posttraumatic stress disorder. Am. J. Psychiatry. 150:1993;1011-1014.
6. Bremner J.D., Scott T.M., Delaney R.C., Southwick S.M., Mason J.W., Johnson D.R., Innis R.B., McCarthy G., Charney D.S. Deficit in short-term memory in posttraumatic stress disorder. Am. J. Psychiatry. 150:1993;1015-1019.
7. Bremner J.D., Randall P., Scott T.M., Bronen R.A., Seibyl J.L., Southwick S.M., Delaney R.C., Mc Carthy G., Charney D.S., Innis R.B. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am. J. Psychiatry. 152:1995;973-981.
8. Bouton, M.E. and Buller, R.C., 1985. Contexts, event memories and extinction. In: Balsam, P.D.D., Tomick, A. (Eds.), Context and Learning. Lawrence Erlbaum Associates, Hillside, NJ, pp. 133-166.
9. Carlsson M.L., Engberg G. Ethanol behaves as an NMDA antagonist with respect to locomotor stimulation in monoamine-depleted mice. J. Neural. Transm. 87:1992;155-160.
10. Carmichael F.J., Israel Y. Effects of ethanol on neurotransmitter release by rat brain cortical slices. J. Pharmacol. Exp. Ther. 193:1975;824-834.
11. Cascella N.G., Macciardi F., Cavallini S.M., Smeraldi E. D-cycloserine adjuvant therapy to conventional neuroleptic therapy in schizophrenia: an open label study. J. Neurol. Transm. 95:1994;105-111.
12. Charness, M.E., 1992. Molecular mechanisms of ethanol intoxication, tolerance and physical dependence. In: Mendelson, J.H., Mello, N.K. (Eds.), Medical Diagnosis and Treatment of Alcoholism. McGraw-Hill International Book Co., New York, pp. 155-199.
13. Charney D.S., Deutsch A.Y., Krystal J.H., Southwick S.M., Davis M. Psychobiologic mechanisms of posttraumatic stress disorder. Arch. Gen. Psychiatry. 50:1993;294-305.
14. Collingridge G.L., Lester R.A.J. Excitatory amino acid receptors in the vertebrate nervous system. Pharmacol. Rev. 40:1989;143-210.
15. Colombo G., Grant K.A. NMDA receptor complex antagonists have ethanol-like discriminative stimulus effects. Ann. NY Acad. Sci. 654:1992;421-423.
16. Cotman C.W., Monaghan D.T. Excitatory amino acids and neurotransmission: NMDA receptor and Hebb-type synaptic plasticity. Ann. Rev. Neurosci. 11:1988;61-80.
17. Crane G.E. Cycloserine as an antidepressant agent. Am. J. Psychiatry. 115:1959;1025-1026.
18. Crane G.E. The psychotropic effects of cycloserine: a new use for an antibiotic. Compr. Psychiatry. 2:1961;51-59.
19. Davidson J. Drug therapy of posttraumatic stress disorder. Br. J. Psychiatry. 160:1992;309-314.
20. Davidson M.D., Wilce P., Shanley B.C. Increased sensitivity of the hippocampus in ethanol-dependent rats to toxic effect of N-methyl-D-aspartic acid in vivo. Brain Res. 606:1993;5-9.
21. Deakin J.F.W., Slater P., Simpson M.D.C., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G.P., Gross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52:1989;1781-1786.
22. Deutsch A.Y., Roth R.M. The determinants of stress-induced activation of the prefrontal cortical dopamine system. Prog. Brain Res. 85:1990;367-403.
23. 2+ in dissociated brain cells. Brain Res. 499:1989;383-387.
24. D'Souza, D.C., Charney, D. and Krystal, J., 1995. Glycine site agonists of the NMDA receptor: a review. In: CNS Drug Reviews. Neva Press, Branford CT, pp. 227-260.
25. Epstein I.G., Nair K.G.S., Boy L.G. The treatment of human tuberculosis with cycloserine. Prog. Rep. Dis. Chest. 29:1955;241-257.
26. Epstein I.G., Nair K.G.S., Mulino M.G. Pyridoxine: its relation to cycloserine toxicity: pharmacological and clinical study. Antibiotics Ann. 5:1959;472-481.
27. Falls W.A., Miserendino M.J.D., Davis M. Excitatory amino acid antagonists infused into the amygdala block extinction of fear-potentiated startle. Soc. Neurosci. Abstr. 16:1990;767.
28. Friedman M.J. Toward rational pharmacotherapy for posttraumatic stress disorder: an interim report. Am. J. Psychiatry. 145:1988;281-285.
29. Gattaz W.F., Gattaz D., Beckmann H. Glutamate in schizophrenics and healthy controls. Arch. Psychiatr. Nerve Kr. 231:1982;221-225.
30. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry. 152:1995;1213-1215.
31. Goldman-Rakic, P.C., 1990. Cellular and circuit basis of working memory in prefrontal cortex of nonhuman primates. In: Uylings, M.B.M., Von Eden, C.G., De Bruin, J.P.C., Corner, H.A., Feenstra, M.P.G. (Eds.), The prefrontal cortex: its structure, function and pathology. Elsevier Science Publishers, Amsterdam, The Netherlands.
32. Goldstein G., van Kammen W., Shelly C., Miller D.J., van Kammen D.P. Survivors of imprisonment in the Pacific theatre during World War II. Am. J. Psychiatry. 144:1987;1210-1213.
33. Goldstein L.E., Rasmussen A.M., Bunney B.S., Roth R.H. The NMDA glycine site antagonist (+)-HA-966 selectively regulates conditioned stress-induced metabolic activation of the mesoprefrontal cortical dopamine but not serotonin systems: a behavioural neuroendocrine and neurochemical study in the rat. J. Neurosci. 14:1994;4937-4950.
34. Gothert M., Fink K. Inhibition of N-methyl-D-aspartate (NMDA) and glutamate-induced noradrenaline and acetylcholine release in the rat brain by ethanol. Naunyn-Schmiederberg's Arch. Pharmacol. 340:1989;516-521.
35. Grant K.A., Valverius P., Tabakoff B. Ethanol withdrawal seizures and the NMDA receptor complex. Eur. J. Pharmacol. 176:1990;289-296.
36. Gulya K., Grant K.A., Valverius P., Hoffman P.L., Tabakoff B. Brain regional specificity and time-course of changes in the NMDA receptor-ionophore complex during ethanol withdrawal. Brain Res. 547:1991;129-134.
37. Handelman G.E., Mueller L.L., Cordi A.A. Glycenergic compounds facilitate memory formation and retrieval in rats. Soc. Neurosci. Abstr. 14:1988;249.
38. Hebb, D.O., 1949. The organisation of behaviour. Wiley, N.Y.
39. Henderson J.L., Moore M. The psychoneurosis of war. N. Engl. J. Med. 230:1944;274-278.
40. Heresco-Levy U., Javitt D.C., Zukin S.R. The phencyclidine (PCP) N-methyl-D-aspartate (NMDA) model of schizophrenia: theoretical and clinical implications. Psych. Annals. 23:1993;135-144.
41. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry. 169:1996;610-617.
42. Heresco-Levy U., Silipo G., Javitt D.C. Glycenergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol. Bull. 32:1996;731-740.
43. Hitchcock J.M., Davis M. Efferent pathways of the amygdala involved in conditioned fear as measured with the fear-potentiated startle paradigm. Behav. Neurosci. 105:1991;826-842.
44. Hoffman P.L., Rabe C.S., Moses I., Tabakoff B. N-methyl-D-aspartate receptors and ethanol: inhibition of calcium flux and cyclic GMP production. J. Neurochem. 52:1989;1937-1940.
45. Hollman M., Heinemann S. Cloned glutamate receptors. Ann. Rev. Neurosci. 17:1994;31-108.
46. Hood W.F., Compton R.P., Monahan J.B. DCS: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci. Lett. 98:1989;91-95.
47. Hu H.-J., Ticku M.K. Chronic ethanol treatment upregulates the NMDA receptor function and binding in mammalian cortical neurons. Mol. Brain Res. 30:1995;347-356.
48. Iorio K.R., Reinlib L., Tabakoff B., Hoffman P.L. Chronic exposure of cerebellar granule cells to ethanol results in increased N-methyl-D-aspartate receptors function. Mol. Pharmacol. 41:1992;1142-1148.
49. Ishimaru M., Kuruma J.I., Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry. 35:1994;84-95.
50. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
51. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.-P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry. 151:1994;1234-1236.
52. Javitt D.C., Frusciante M. Glycyldodecylamide, a phencyclidine behavioural antagonist, blocks cortical glycine uptake: Implications for schizophrenia and substance abuse. Psychopharmacology. 3:1996;207-210.
53. Johnson J.W., Asher P. Glycine potentates the NMDA response in cultured mouse brain neurons. Nature. 323:1987;529-531.
54. Johnson S.W., Seutin V., North R.A. Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. Science. 258:1992;665-667.
55. Jones R.W., Wesnes K.A., Kirby J. Effects of NMDA modulation in scopolamine dementia. Ann. NY Acad. Sci. 640:1991;241-244.
56. Kalb R.G. Current excitement about the glutamate receptor family. Neuroscientist. 1:1995;60-67.
57. Kalivas P.W., Duffy P., Barrow J. Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J. Pharmacol. Therapeutics. 251:1989;378-387.
58. Kendig I.V., Charen S., Lepine L.T. Psychological side effects induced by cycloserine in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 73:1956;438-441.
59. Kerwin R.W., Patel S., Meldrum B.S., Czudek G., Reynolds G.P. Asymmetrical loss of glutamate receptors subtype in left hippocampus in schizophrenia. Lancet. 1:1988;583-584.
60. Kerwin R.W., Patel S., Meldrum B. Quantitative autoradiographic analysis at glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience. 39:1990;25-32.
61. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
62. Kleinschmidt A., Bear M.F., Singer W. Blockade of NMDA receptors disrupts experience-dependent plasticity of kitten striate cortex. Science. 238:1987;355-358.
63. Knopfel T.H., Zeise M.L., Cuenod M., Zieglgansberger W. L-Homocysteic acid but no L-glutamate is an endogenous N-methyl-D-aspartic acid receptor preferring agonist in rat neocortical neurons in vitro. Neurosci. Lett. 81:1987;188-192.
64. 3H] MK-801 binding sites in postmortem brain regions of schizophrenic patients. J. Neurol. Transm. Park. Dis. Dement. Sect. 77:1989;231-236.
65. Kotlinska J., Liljequist S. Oral administration of glycine and polyamine receptor antagonists blocks ethanol withdrawal seizures. Psychopharmacology. 177:1996;238-244.
66. Kotter H. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol. 44:1994;163-196.
67. Krystal J.M., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist ketamine in humans. Arch. Gen. Psychiatry. 51:1994;199-214.
68. Krystal, J.M., Petrakis, I., Trevisan, L., Webb, E., Cooney, N., Karper, L.P., Namanworth, S., Casal, L., D'Souza, D.C., Heninger, G., Charney, D.S., 1995. Clinical evidence implicating NMDA receptors in ethanol effects and alcoholism. In: Abstracts, 34th Annual Meeting of the American College of Neuropsychopharmacology, December 1995, Puerto Rico, p. 60.
69. Kulkarni S.K., Mehta A.K., Ticku M.K. Comparison of anticonvulsant effect of ethanol against NMDA-, Kainic acid-and picrotoxin-induced convulsions in rats. Life Sci. 46:1990;481-487.
70. LeDoux J.E., Iwata J., Cichetti P., Reis D.J. Different projections of the central amygdaloid nucleus mediate autonomic and behavioural correlates of conditioned fear. J. Neurosci. 8:1988;2517-2529.
71. Lester W. Jr., Salomon A., Neiman A. Cycloserine therapy of tuberculosis in humans. Am. Rev. Tuberc. 74:1956;121-127.
72. Lilljequist S. NMDA receptor antagonists inhibit ethanol- produced locomotor stimulation in NMRI mice. Alcohol. 8:1991;309-312.
73. Lima-Landman, M.T.R., Albuquerque, E.X., 1989. Ethanol potentiates and blocks NMDA-activated single-channel currents in rat hippocampal pyramidal cells. FEBS Lett., 61-67.
74. Linden D.J., Connor J.A. Cellular mechanisms of long-term depression in the cerebellum. Curr. Opin. Neurobiol. 3:1993;401-406.
75. Litten R.Z., Allen J.P. Pharmacotherapies for alcoholism: promising agents and clinical issues. Alcohol Clin. Exp. Res. 15:1991;620-633.
76. Lovinger D.M., White F.F. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science. 234:1989;1721-1724.
77. Malenka R.C., Nicoll R.A. NMDA receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci. 16:1993;521-527.
78. Mandell, U.L., Sorple, M.A., 1985. Drugs used in chemotherapy of tuberculosis and leprosy. In: Goodman, L.S., Gilman, A.G. (Eds.) The pharmacological basis of therapeutics. Macmillan, New York, pp. 1199-1218.
79. Martin D., Swartzwelder H.S. Ethanol inhibits release of excitatory amino acids from slices of hippocampal area CA1. Eur. J. Pharmacol. 219:1992;469-472.
80. McAllister W.R., McAllister D.E. Reconditioning of extinguished fear after a one-year delay. Bull. Psychonomic. Soc. 26:1988;463-466.
81. McNally R.J., English G.E., Lipke H.J. Assessment of intrusive cognition in PTSD: use of the modified Stroop paradigm. J. Traumatic Stress. 6:1993;33-41.
82. Michaelis E.K., Mulvaney M.J., Freed W.J. Effects of acute and chronic ethanol intake on synaptosomal glutamate binding activity. Biochem. Pharmacol. 27:1978;1685-1691.
83. Miserendino M.J.D., Sananes C.B., Melia K.R., Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature. 345:1990;716-718.
84. Monahan J.B., Handelman G.E., Hood W.F. DCS, a positive modulator of N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol. Biochem. and Behaviour. 34:1989;649-653.
85. Morris R.G.M., Anderson E., Lynch G.S., Haudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 319:1986;774-776.
86. Morrisett R.A., Martin D., Oetting T.A., Lewis D.V., Wilson W.A., Swartzwelder H.S. Ethanol and magnesium ions inhibit N-methyl-D-aspartate-mediated synaptic potentials in an interactive manner. Neuropharmacology. 30:1991;1173-1178.
87. Muir K.W., Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
88. Nemeroff C.B. Evolutionary trends in the pharmaco-therapeutic management of depression. J. Clin. Psychiatry. 12(suppl.):1994;3-15.
89. Nicoll R.A., Kaner J.A., Malenka R.C. The current excitement in long-term potentiation. Neuron. 1:1988;97-103.
90. Nie Z., Yuan X., Madamba S.G., Siggins G.R. Ethanol decreases glutamatergic synaptic transmission in rat nucleus accumbens in vitro: naloxone reversal. J. Pharmacol. Exp. Ther. 266:1993;1705-1712.
91. 3H kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci. Lett. 40:1983;245-250.
92. Nowak G., Trullas R., Layer R.T., Skolnick P., Paul I.A. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclo-propanecarboxylic acid. J. Pharmacol. Exp. Ther. 265:1993;1380-1386.
93. Nowak G., Ordway G.A., Paul I.A. Alteration in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 675:1995;157-164.
94. Oldendorph W.M. Brain uptake of radio labeled amino acids, amines and hexoses after arterial injection. Am. J. Physiol. 221:1971;1629-1639.
95. Olney J.W. Excitatory amino acids and neuropsychiatric disorders. Biol. Psychiatry. 26:1989;505-525.
96. Ostrovskii, V.I., Stankovskaya, S.Y., Ostrovskii, S.Y., 1988. Metabolic reason and consequence of use of alcohol. Minsky, pp. 5-8 (in Russian).
97. Paul I.A., Layer R.T., Skolnick P., Nowak G. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur. J. Pharmacol. 247:1993;305-311.
98. Paul I.A., Nowak G., Layer R.T., Popik P., Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. 269:1994;95-102.
99. 3H ] MK-801 binding in Alzheimer's disease. J. Neurochem. 53:1989;698-704.
100. Rabe C.S., Tabakoff B. Glycine site-directed agonists reverse the actions of ethanol at the N-methyl-D-aspartate receptor. Mol. Pharmaco. 38:1990;753-757.
101. Richelson E. Synaptic pharmacology of antidepressants: an update. McLean Hosp. J. 13:1988;67-88.
102. Rosse F.B., Schwartz B.L., Davis R.E., Deutsch S.I. An NMDA intervention strategy in schizophrenia with low dose milacemide. Clin. Neuropharmacol. 14:1991;268-272.
103. Samson H.H., Harris R.A. Neurobiology of alcohol abuse. Trends Pharmacol. Sci. 13:1992;206-211.
104. A and NMDA receptor function in the rat brain. Alcohol Clin. Exp. Res. 17:1993;115-123.
105. Sass H., Soyka M., Mann K., Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Psychiatry. 53:1996;673-680.
106. Schatzberg, A.F., 1988. Depressive disorders. In: Tupin, J.P., Shader, R.I., Hartnett, D.S. (Eds.), Handbook of clinical psychopharmacology. Jason Arneson, Northvale NJ, pp. 49-71.
107. Schechter M.D., Meehan S.M., Gordon T.L., McBurney D.M. The NMDA. receptor antagonist MK-801 produces ethanol-like discrimination in the rat. Alcohol. 10:1993;197-201.
108. Sherman A.D., Davidson A.T., Baruah S., Heywood T.S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci. Lett. 121:1991;77-80.
109. Simpson M.D.C., Slater P., Royston M.C., Deakin J.F.W. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Res. 42:1992;273-282.
110. Simson P.E., Criswell H.E., Johnson K.B., Hicks R.E., Breese G.R. Ethanol inhibits NMDA-evoked electro-physiological activity in vivo. J. Pharmacol. Exp. Ther. 252:1991;225-231.
111. Skolnick P., Miller R., Young A., Roje K., Trullas R. Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioural responses to compounds active at the N-methyl-D-aspartate receptor complex. Psychopharmacology. 107:1992;489-496.
112. Sutker P.B., Galina Z.H., West J.A., Allain A.N. Trauma-induced weight loss and cognitive deficits among former prisoners of war. J. Consult. Clin. Psychol. 58:1990;323-328.
113. Sutker P.B., Winstead D.K., Galina Z.H., Allain A.N. Cognitive deficits and psychopathology among former prisoners of war and combat veterans of the Korean conflict. Am. J. Psychiatry. 148:1991;67-72.
114. Takadera T., Suzuki R., Mohri T. Protection by ethanol of cortical neurons from N-methyl-D-aspartate-induced neurotoxicity is associated with blocking calcium influx. Brain Res. 537:1990;109-114.
115. Tamminga, C.A., Cascella, N., Fakouhi, T.D., Herting, R.L., 1992. Enhancement of NMDA-mediated neurotransmission in schizophrenia. In: Meltzer, H.Y. (Ed.), Novel antipsychotic drugs. Raven Press, New York, pp. 171-177.
116. Teyler T.J., Discenna P. Long-term potentiation. Ann. Rev. Neurosci. 10:1987;131-161.
117. Thomas J.T. Excitatory amino acids in health and disease. J. Am. Ger. Soc. 43:1995;1279-1289.
118. Tonkiss J., Morris R.G.M., Rowlins J.N.P. Intraventricular infusion of the NMDA antagonist AP5 impairs performance on a nonspatial operant task in the rat. Exp. Brain Res. 73:1988;181-188.
119. Toth E., Lajtha A. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem. Res. 11:1986;393-400.
120. Trullas R., Skolnick P. Functional antagonists of the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185:1990;1-10.
121. Tsai G., Passani L.A., Slusher B.S., Carter L., Baer L., Kleinman J.E., Coyle J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry. 52:1995;829-836.
122. Tsai G., Gutfriend D.R., Coyle J.T. The glutamatergic basis of human alcoholism. Am. J. Psychiatry. 153:1995;332-340.
123. Uddo M., Vasterling J.J., Brailey K., Sutker P.B. Memory and attention in post-traumatic stress disorder. J. Psychopathol. Beh. Assessment. 15:1993;43-52.
124. Waziri R. Glycine therapy of schizophrenia. Biol. Psych. 23:1988;210-211.
125. Whittington M.A., Lambert J.D.C., Little H.J. Increased NMDA-receptor and calcium channel activity during ethanol withdrawal hyperexcitability. Alcohol. 30:1995;105-114.
126. Worosec, A., 1959. Discussion. In: Abstracts, 17th Conference on chemotherapy of tuberculosis. Veterans Administration-U.S. Armed Forces, p. 39.
127. Yehuda R., Keefe S.E., Harvey P.D., Levengood R.A., Gerber D.K., Geni J., Siever L.J. Learning and memory in combat veterans with posttraumatic stress disorder. Am. J. Psychiatry. 152:1995;137-139.
128. Zeise H.L., Kasparow S., Capogna M., Zieglgänsberger W. Acamprosate (calcium homotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur. J. Pharmacol. 231:1993;47-52.
129. Zeise, M., Madamba, S.G., Siggins, G.R., Putske, J., Zieglgänsberger, W., 1994. The anticraving substance acamprosate reduces glutamatergic synaptic transmission and a high-threshold calcium current in neocortical and hippocampal neurons. Alcohol Clin. Exp. Res. 82, Abstract.
130. Zieglgansberger, W. and Zeise, M., 1992. Calcium di-acetyl-homotaurinate which prevents relapse in weaned alcoholics decreases the action of excitatory amino acids in neocortical neurons of the rat in vitro. In: Sellers, E.M., Naranjo, C.A. (Eds.). Novel pharmacological interventions for alcoholism. Springer-Verlag NY Inc., New York, pp. 337-341.